PL4037685T3 - Chinolina modulująca serca i jej zastosowanie w leczeniu chorób - Google Patents
Chinolina modulująca serca i jej zastosowanie w leczeniu choróbInfo
- Publication number
- PL4037685T3 PL4037685T3 PL21845832.1T PL21845832T PL4037685T3 PL 4037685 T3 PL4037685 T3 PL 4037685T3 PL 21845832 T PL21845832 T PL 21845832T PL 4037685 T3 PL4037685 T3 PL 4037685T3
- Authority
- PL
- Poland
- Prior art keywords
- serca
- quinoline
- modulate
- treating disease
- disease
- Prior art date
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/932,832 US20200347038A1 (en) | 2014-08-29 | 2020-07-20 | Quinolines that modulate serca and their use for treating disease |
| PCT/US2021/042235 WO2022020261A1 (en) | 2020-07-20 | 2021-07-19 | Quinolines that modulate serca and their use for treating disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4037685T3 true PL4037685T3 (pl) | 2024-04-02 |
Family
ID=79729478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21845832.1T PL4037685T3 (pl) | 2020-07-20 | 2021-07-19 | Chinolina modulująca serca i jej zastosowanie w leczeniu chorób |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4037685B9 (pl) |
| JP (1) | JP7705445B2 (pl) |
| CN (1) | CN116744928A (pl) |
| CA (1) | CA3186668A1 (pl) |
| DK (1) | DK4037685T3 (pl) |
| ES (1) | ES2968041T3 (pl) |
| FI (1) | FI4037685T3 (pl) |
| HU (1) | HUE064550T2 (pl) |
| PL (1) | PL4037685T3 (pl) |
| PT (1) | PT4037685T (pl) |
| WO (1) | WO2022020261A1 (pl) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009014235A (es) * | 2007-08-22 | 2010-04-27 | Abbott Gmbh & Co Kg | 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso. |
| US20200347038A1 (en) * | 2014-08-29 | 2020-11-05 | Russell Dahl | Quinolines that modulate serca and their use for treating disease |
| US10772881B2 (en) * | 2017-02-27 | 2020-09-15 | Russell Dahl | Quinolines that modulate SERCA and their use for treating disease |
| US20170281611A1 (en) * | 2014-08-29 | 2017-10-05 | Eiger Biopharmaceuticals, Inc. | Quinolines and their use for treating endoplasmic reticulum stress-caused diseases |
| CN106966973A (zh) * | 2017-05-18 | 2017-07-21 | 湖北工业大学 | N‑苯基‑n‑(2‑甲基‑8‑喹啉基)苯甲酰胺的制备方法 |
-
2021
- 2021-07-19 EP EP21845832.1A patent/EP4037685B9/en active Active
- 2021-07-19 ES ES21845832T patent/ES2968041T3/es active Active
- 2021-07-19 PT PT218458321T patent/PT4037685T/pt unknown
- 2021-07-19 FI FIEP21845832.1T patent/FI4037685T3/fi active
- 2021-07-19 HU HUE21845832A patent/HUE064550T2/hu unknown
- 2021-07-19 PL PL21845832.1T patent/PL4037685T3/pl unknown
- 2021-07-19 CN CN202180063849.1A patent/CN116744928A/zh active Pending
- 2021-07-19 JP JP2023504102A patent/JP7705445B2/ja active Active
- 2021-07-19 WO PCT/US2021/042235 patent/WO2022020261A1/en not_active Ceased
- 2021-07-19 CA CA3186668A patent/CA3186668A1/en active Pending
- 2021-07-19 DK DK21845832.1T patent/DK4037685T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022020261A9 (en) | 2022-09-09 |
| ES2968041T3 (es) | 2024-05-06 |
| JP7705445B2 (ja) | 2025-07-09 |
| PT4037685T (pt) | 2023-12-28 |
| EP4037685A4 (en) | 2022-11-30 |
| HUE064550T2 (hu) | 2024-03-28 |
| FI4037685T3 (fi) | 2023-11-27 |
| CN116744928A (zh) | 2023-09-12 |
| EP4037685A1 (en) | 2022-08-10 |
| DK4037685T3 (en) | 2024-01-02 |
| JP2023534992A (ja) | 2023-08-15 |
| EP4037685B1 (en) | 2023-09-20 |
| WO2022020261A1 (en) | 2022-01-27 |
| CA3186668A1 (en) | 2022-01-27 |
| EP4037685B9 (en) | 2024-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3968916A4 (en) | GLAND TREATMENT DEVICES AND METHODS FOR TREATMENT OF DRY EYES | |
| IL285649A (en) | Azepino-indoles and other heterocyclics for the treatment of brain disorders | |
| IL268327A (en) | A pharmaceutical preparation for use in the treatment and prevention of c5-related diseases and methods for the treatment and prevention of c5-related diseases | |
| ZA201905222B (en) | Combination treating prostate cancer, pharmaceutical composition and treatment method | |
| IL276247A (en) | Methods and materials for the treatment of sleep apnea | |
| IL280413A (en) | Bismuth-thiol preparations and wound treatment methods | |
| HUE073261T2 (hu) | Készítmények fehérje-aggregációs betegségek kezelésére és/vagy megelõzésére | |
| IL285197A (en) | Methods and preparations for the treatment of sleep apnea | |
| IL304273A (en) | Compositions and methods for treating Fabry disease | |
| IL275875A (en) | Treatment and prevention of sleep disorders | |
| EP4334718A4 (en) | ASSESSMENT AND TREATMENT OF CANCER | |
| DK4037685T3 (en) | Quinoline that modulate serca and its use for treating disease | |
| IL288178A (en) | Combined gmci and ddri treatment for cancer | |
| SI3630112T1 (sl) | Kombinacija regorafeniba in nivolumaba za zdravljenje raka | |
| ZA202002526B (en) | New alcoxyamino derivatives for treating pain and pain related conditions | |
| IL290403A (en) | Prevention and treatment of hypoglycemia | |
| IL291609A (en) | Methods for treating acute wounds and improving outcomes | |
| EP4085908A4 (en) | PHARMACEUTICAL COMBINATION FOR TREATING TUMORS AND ITS APPLICATION | |
| HK40113459A (en) | Medicament for preventing and/or treating dry eye | |
| HK40039991A (en) | Sleep disorder treatment and prevention | |
| HK40104254A (en) | Methods and agents that stimulate mitochondrial turnover for treating disease | |
| SG11202108026UA (en) | Neurotensinergic agonists and methods of using same preventing or treating pain | |
| IL288524A (en) | Methods of treatment or prevention of eczema | |
| HK40066255A (en) | Preventing and treating hypoglycemia | |
| HK40071066A (en) | Gmci and ddri combination therapy for treating cancer |